What ZIG Ventures does

ZIG Ventures is a Singapore-based venture investment and commercialization company focused on early-stage healthcare and biomedical technology companies across the Asia Pacific region. Founded in 2014 as the corporate venturing arm of Zicom Group and demerged in 2018 to operate independently, the firm identifies early-stage medtech innovations in oncology, ophthalmology, healthcare analytics, and life sciences, and actively develops them by working side-by-side with founders to build capabilities and drive commercialization. Its disclosed portfolio of five companies—Biobot Surgical, Histoindex, Curiox Biosystems, Pellucid, Endofotonics, and BELKIN Laser—spans robotic surgery, bioinstrumentation, AI-assisted cancer detection, and ophthalmic devices.

ZIG's business model combines equity investment with an operational commercialization layer. The wholly-owned subsidiary ZIG MedTech Asia provides Asia Pacific market entry services, including product registration, market penetration, and distributorship management, while ZIG itself acts as the global distributor for products such as Biobot Surgical's iSR'obot Mona Lisa robotic biopsy system. The firm is a co-investment partner of SEEDS Capital under Singapore's Startup SG Equity scheme and since March 2021 has been a partner under the Enterprise Singapore Innovation and Enterprise Fellowship (IFP) Programme, which feeds its ZIG Innovation Fellowship talent pipeline. Capital deployment is led by Chairman Sim Giok Lak and CEO Sim Kok Hwee, with the firm holding board representation across key portfolio companies.

ZIG's revenue mechanics are typical of a venture platform: returns are generated through equity stakes in early-stage medtech companies, with realizations occurring via IPOs, follow-on rounds, and acquisitions. The August 2023 KOSDAQ IPO of cornerstone portfolio company Curiox Biosystems (1,400,000 shares at 13,000 won per share) is a recent successful exit, while ongoing rounds such as the $7.85M Biobot Surgical financing led by ZIG (2026) and the $12.25M BELKIN Laser Series B (2020) reflect continued capital deployment. The firm does not disclose AUM, management fees, carry, or firm-level revenue.

Name

ZIG Ventures

Legal name

ZIG Ventures Limited

Website

https://ziggroup.com.sg

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

ZIG Ventures is a Singapore-based venture investment and commercialization company that backs early-stage medtech companies across Asia Pacific, providing capital, operational support, and APAC market entry through its ZIG MedTech Asia subsidiary and global distribution relationships.

Ownership category

akta.pro rank

Product category

Venture Capital / Healthcare Commercialization Services

NAICS

Management Consulting Services (54161)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC)

akta.pro secondary industries

Corporate Innovation & Technology Scouting Units (with investment mandate) (FSANAHAI), Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF), Strategy & Corporate Development Consulting (BPAHACAA)

Keywords

• Venture capital investing
• Healthcare commercialization
• Medtech investments
• Life sciences venture
• Medical device distribution

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Venture Capital Returns: ZIG Ventures generates returns through equity investments in early-stage healthcare medtech companies, providing capital in exchange for ownership stakes. Returns are realized through IPO exits, follow-on funding rounds, and acquisitions of portfolio companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

ZIG Ventures is a venture investment and commercialization company that invests in early-stage healthcare biomedical technology companies in the Asia Pacific region. It works alongside founders to build capabilities and drive commercialization through its dedicated commercialization arm, ZIG MedTech Asia, which supports product registration, market penetration, and distributorship management across Asia Pacific. The firm also acts as the appointed global distributor for select portfolio products such as Biobot Surgical's iSR'obot Mona Lisa.

Product overview

ZIG Ventures is a venture investment and commercialization platform focusing on healthcare innovations in the Asia Pacific region. The company invests in healthcare biomedical technology companies and actively develops them by working with founders, building capabilities, and driving commercialization. ZIG MedTech Asia serves as the commercialization arm supporting product registration, market penetration, and distributorship management in the Asia Pacific region. The portfolio includes: Biobot Surgical's iSR'obot™ Mona Lisa robotic biopsy system; Curiox Biosystems' Laminar Wash™ product line (HT1000, AUTO 1000, and MINI) for automated sample preparation; Endofotonics' SPECTRA IMDx™ AI-powered Raman spectroscopy system for early gastric cancer detection; BELKIN Laser's one-second glaucoma laser treatment device; and portfolio companies Histoindex and Pellucid.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Successful IPO exit of Curiox Biosystems on KOSDAQ in August 2023
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Partnerships

One partnership is on record.

• ZIG MedTech AsiacoreStrategic or Co-development Partner · 1 January 2018ZIG MedTech Asia is the commercialization arm of ZIG Ventures established to work closely with portfolio companies to support product registration, market penetration, and distributorship management activities in the Asia Pacific region.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• SEEDS Capital: Direct co-investment partner of ZIG Ventures under the Startup SG Equity scheme. SEEDS Capital is a wholly-owned entity of Enterprise Singapore that co-invests in Singapore-based early-stage startups, sharing deal-flow, governance frameworks, and government backing.
• SGInnovate: Singapore government-linked deep-tech investor that funds and builds science-based startups, particularly in healthcare and biomedical sciences. Comparable as a Singapore-anchored deep-tech commercialization platform.
• Heritas Capital: Singapore-based venture and growth investor focused on healthcare and deep-tech, with similar mandate of backing early-stage health and life-sciences innovators across Asia. Directly comparable in sector focus and stage.

Others

• Zicom Group: Former parent of ZIG Ventures prior to the 2018 demerger. Zicom is a diversified engineering and manufacturing business, providing context on ZIG's origins as a corporate venturing arm and potential ecosystem overlap.
• Enterprise Singapore: Singapore government agency that operates SEEDS Capital and the IFP program through which ZIG accesses co-investment capital and talent. Functioning as an LP/co-investor ecosystem enabler rather than a direct competitor.

Broad incumbents

• Novo Holdings: Denmark-based holding company of the Novo Nordisk Foundation with significant healthcare and life-sciences venture investing arm. Comparable as a mission-driven, healthcare-focused investor with long-duration capital, though at much greater scale.
• CBC Group: Asia's largest healthcare-dedicated investment firm spanning venture, growth, and buyout across the region. Comparable in healthcare-only mandate but operates at materially larger scale and AUM.
• OrbiMed Advisors: Global healthcare-dedicated investment firm across venture, growth, and public equity. Comparable in healthcare-only thematic focus but with significantly broader geographic footprint and larger fund vehicles.
• RA Capital Management: Healthcare-focused investment manager operating across public and private markets. Comparable in healthcare-only thesis and crossover investing into clinical-stage assets, though at materially larger scale.
• ARCH Venture Partners: US-based early-stage venture firm specializing in life sciences, physical sciences and cleantech. Comparable in deep-tech/healthcare focus and willingness to incubate companies from research institutions, though much larger AUM.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZIG Ventures